全球肌萎縮疾病市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

全球肌肉萎縮症（MUD）市場預計將從2025年的269.1億美元成長至2034年的996.8億美元，並預計在2026年至2034年間以15.66%的複合年成長率成長。全球MUD市場穩定成長的原因在於肌肉萎縮症和惡病質等疾病的盛行率不斷上升。人口老化和慢性病發病率的增加也促使人們對有效療法的需求日益成長。生物技術和基因治療研究的進步正在推動創新療法的開發。此外，疾病認知度的提高和診斷能力的提升也進一步促進了市場擴張。

關鍵成長要素包括對罕見疾病研究投入的增加和監管獎勵的支持。製藥公司正專注於標靶治療和個人化醫療方法。臨床試驗的擴展以及研究機構與生物技術公司之間的合作正在加速創新。此外，新興國家醫療基礎設施的改善也提高了病患獲得治療的機會。

未來，基因編輯和再生醫學的進步有望推動該市場的發展。早期診斷和支持性治療方案將改善患者的治療效果。罕見疾病研究經費的增加將開闢新的成長途徑。在科學不斷突破的背景下，全球肌肉營養不良症市場預計將持續成長。

我們的報告經過精心撰寫，旨在提供涵蓋廣泛行業和市場的全面且切實可行的洞察。每份報告都包含幾個關鍵組成部分，旨在幫助您全面了解市場環境：

市場概覽：本節對市場進行了清晰的說明，包括關鍵定義、分類以及當前行業格局的概述。

市場動態：對影響市場成長的主要促進因素、阻礙因素、機會和挑戰進行詳細評估。這包括技術發展、法律規範和不斷變化的行業趨勢等因素。

市場區隔分析：本部分根據產品類型、應用、最終用戶和地區將市場系統性地分類為若干關鍵細分市場。本部分揭示了每個細分市場的表現、成長潛力和市場貢獻。

競爭格局：我們對主要市場參與企業進行了詳細評估，包括其市場定位、產品系列、策略舉措和財務表現。這有助於深入了解競爭趨勢和主要參與者所採取的策略。

市場預測：本部分提供基於數據的市場規模和成長模式預測，預測期為特定時期。它綜合考慮了歷史趨勢、當前市場狀況和定量分析，以識別未來預期趨勢。

區域分析：我們全面檢驗主要地理區域的市場表現，識別高成長領域和區域趨勢，並深入了解區域市場機會。

新趨勢與新機會：識別關鍵市場趨勢、技術進步和新興投資機會。本部分重點在於潛在成長領域和未來產業趨勢。

客製化選項：我們提供靈活的報告客製化服務，以滿足您的特定需求。這包括額外的細分、國家/地區分析、競爭對手分析、客製化資料點或針對特定細分市場的洞察，以更好地支援您的策略決策。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章 全球肌肉萎縮症市場：依類型分類

• 市場分析、洞察與預測
• 肌肉萎縮症
• 肌肉萎縮

第5章 全球肌肉萎縮症市場：依治療類型分類

• 市場分析、洞察與預測
• 製藥
• 物理治療
• 營養療法
• 外科手術
• 基因治療
• 其他

第6章 全球肌肉萎縮症市場：依最終用戶分類

• 市場分析、洞察與預測
• 醫院
• 復健中心
• 專科診所
• 其他

第7章 全球肌肉萎縮症市場：依地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 西班牙
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 中國
  • 日本
  • 韓國
  • 印度
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第8章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第9章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Sarepta Therapeutics
  • Biogen
  • Roche
  • Sanofi
  • Scholar Rock
  • Regeneron
  • Avidity Biosciences
  • Dyne Therapeutics
  • Arrowhead Pharmaceuticals
  • Wave Life Sciences
  • PepGen
  • Solid Biosciences
  • Edgewise Therapeutics
  • Capricor Therapeutics
  • Entrada Therapeutics
  • Regenxbio
  • Pfizer
  • Novartis
  • Ionis Pharmaceuticals
  • BioMarin

The global muscle wasting disorders market size is expected to reach USD 99.68 Billion in 2034 from USD 26.91 Billion in 2025, growing at a CAGR of 15.66% during 2026-2034.The Global Muscle Wasting Disorders Market is growing steadily due to increasing prevalence of conditions such as muscular dystrophy and cachexia. Rising aging populations and higher incidence of chronic diseases are contributing to demand for effective treatment options. Advances in biotechnology and gene therapy research are supporting the development of innovative therapies. Growing awareness and improved diagnostic capabilities are further driving market expansion.

Key growth drivers include increased investment in rare disease research and supportive regulatory incentives. Pharmaceutical companies are focusing on targeted therapies and personalized medicine approaches. Expanding clinical trials and collaboration between research institutions and biotech firms are accelerating innovation. Additionally, improved healthcare infrastructure in emerging economies is enhancing access to treatment.

Looking ahead, the market is expected to benefit from advancements in gene editing and regenerative medicine. Early diagnosis and supportive care programs will improve patient outcomes. Increased funding for rare disease research will create new growth avenues. As scientific breakthroughs continue, the Global Muscle Wasting Disorders Market is projected to witness sustained development.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Type

• Muscular Dystrophy
• Muscular Atrophy

By Treatment Type

• Medications
• Physical Therapy
• Nutritional Therapy
• Surgery
• Gene Therapy
• Others

By End-user

• Hospitals
• Rehab Centers
• Specialty Clinics
• Others

COMPANIES PROFILED

• Sarepta Therapeutics, Biogen, Roche, Sanofi, Scholar Rock, Regeneron, Avidity Biosciences, Dyne Therapeutics, Arrowhead Pharmaceuticals, Wave Life Sciences, PepGen, Solid Biosciences, Edgewise Therapeutics, Capricor Therapeutics, Entrada Therapeutics, Regenxbio, Pfizer, Novartis, Ionis Pharmaceuticals, BioMarin

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL MUSCLE WASTING DISORDERS MARKET: BY TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Type
• 4.2. Muscular Dystrophy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Muscular Atrophy Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL MUSCLE WASTING DISORDERS MARKET: BY TREATMENT TYPE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Treatment Type
• 5.2. Medications Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Physical Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Nutritional Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Surgery Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Gene Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL MUSCLE WASTING DISORDERS MARKET: BY END-USER 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End-user
• 6.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Rehab Centers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Specialty Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL MUSCLE WASTING DISORDERS MARKET: BY REGION 2022-2034 (USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Type
  • 7.2.2 By Treatment Type
  • 7.2.3 By End-user
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Type
  • 7.3.2 By Treatment Type
  • 7.3.3 By End-user
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Spain
  • 7.3.9 Russia
  • 7.3.10 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Type
  • 7.4.2 By Treatment Type
  • 7.4.3 By End-user
  • 7.4.4 China
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 India
  • 7.4.8 Australia
  • 7.4.9 South East Asia
  • 7.4.10 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Type
  • 7.5.2 By Treatment Type
  • 7.5.3 By End-user
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Type
  • 7.6.2 By Treatment Type
  • 7.6.3 By End-user
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL MUSCLE WASTING DISORDERS INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Sarepta Therapeutics
  • 9.2.2 Biogen
  • 9.2.3 Roche
  • 9.2.4 Sanofi
  • 9.2.5 Scholar Rock
  • 9.2.6 Regeneron
  • 9.2.7 Avidity Biosciences
  • 9.2.8 Dyne Therapeutics
  • 9.2.9 Arrowhead Pharmaceuticals
  • 9.2.10 Wave Life Sciences
  • 9.2.11 PepGen
  • 9.2.12 Solid Biosciences
  • 9.2.13 Edgewise Therapeutics
  • 9.2.14 Capricor Therapeutics
  • 9.2.15 Entrada Therapeutics
  • 9.2.16 Regenxbio
  • 9.2.17 Pfizer
  • 9.2.18 Novartis
  • 9.2.19 Ionis Pharmaceuticals
  • 9.2.20 BioMarin